GlaxoSmithKline PLC (GSK)

GSK (NYSE:Drugs) EQUITY
$39.76
pos +0.00
+0.00%
Today's Range: 38.91 - 39.77 | GSK Avg Daily Volume: 3,656,100
Last Update: 02/12/16 - 4:00 PM EST
Volume: 0
YTD Performance: -1.46%
Open: $0.00
Previous Close: $39.15
52 Week Range: $37.24 - $49.08
Oustanding Shares: 2,434,895,848
Market Cap: 95,326,172,449
6-Month Chart
TheStreet Ratings Grade for GSK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 3
Moderate Buy 0 0 0 0
Hold 4 4 4 5
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.33 2.33 2.33 2.56
Latest Dividend: 1.25
Latest Dividend Yield: 6.03%
Dividend Ex-Date: 02/17/16
Price Earnings Ratio: 13.45
Price Earnings Comparisons:
GSK Sector Avg. S&P 500
13.45 7.70 26.86
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-0.72% -13.47% -12.62%
GROWTH 12 Mo 3 Yr CAGR
Revenue -18.10 -0.17 -0.06
Net Income 181.50 0.62 0.17
EPS 189.50 0.72 0.20
Earnings for GSK:
EBITDA 6.13B
Revenue 35.44B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $n.a. $n.a. $2.71 $2.77
Number of Analysts 0 0 6 5
High Estimate $n.a. $n.a. $3.32 $2.94
Low Estimate $n.a. $n.a. $2.46 $2.62
Prior Year $0.48 $0.53 $2.26 $2.71
Growth Rate (Year over Year) n.a.% n.a.% 19.91% 2.07%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Dividend yield is the determining factor in this strategy.

Novice Trade: GlaxoSmithKline Real Money Pro($)

Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.
If you have an appetite for risk, there are buying opportunities.
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
This trio enjoys competitive advantages that should serve investors well over the long haul.
Use $24 or $26 as a stop point. 
The stock has put in a tradable low that can support a respectable rally that could carry into early 2016.
Pernix looks poised for a strong 2016.
The charts show that the stock is due for a rally.
Eli Lilly has bucked the downtrend in other pharma names, and its chart is pointed higher.

Columnist Conversations

Judge Smails embarrassed me into writing it!
Some pretty obvious selling in the FATMAN names vs the Nasdaq futures post regular session open. FATM...
You can see the time/price support on the daily chart of SPX below. It also shows you the next major decision ...
$185.80 Exhausted and a long weekend. Column up shortly Sold some IWM as well.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.